



Images are representative and shown for illustrative purposes only. Device images are intended solely to demonstrate relative differences in device size and are not intended to be a comparison of clinical efficacy or safety.

INDICATION

neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 15 kg or greater.

IMPORTANT SAFETY INFORMATION

It is recommended that patients are prescribed and have immediate access to two **neffy** nasal sprays at all times. In the absence of clinical improvement or if symptoms worsen after initial treatment, administer a second dose of **neffy** in the same nostril with a new nasal spray *starting 5 minutes after the first dose*.

neffy is for use in the nose only.


Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required.

Please see additional Important Safety Information for **neffy** on the next page.

Please see full [Prescribing Information](#) for **neffy**.

Bring needle-free epinephrine into your practice.

Scan the code or visit neffyPRO.com to request a demo kit



DOSE	1 mg	2 mg
PATIENT WEIGHT IN INDICATION	33-66 lbs (15-30 kg)	≥66 lbs (≥30 kg)
METHOD OF ADMINISTRATION	Nasal spray	
EXTENDED SHELF LIFE	2 years after its manufacture date ²	2.5 years after its manufacture date ²
DEVICE DIMENSIONS	2.25 x 1.75 x 0.75 in (5.72 x 4.45 x 1.91 cm)	
STORAGE/HEAT TOLERABILITY	neffy can be accidentally exposed to temperatures up to 122°F (50°C). Simply store neffy at room temperature, between 68°F to 77°F (20°C to 25°C).¹ Do not freeze neffy. neffy freezes below 5°F (-15°C). If neffy is accidentally frozen, the device will not spray; however, neffy can be thawed at room temperature for 20 minutes without damage to the device or the epinephrine.²	

IMPORTANT SAFETY INFORMATION (CONT'D)

Absorption of **neffy** may be affected by underlying structural or anatomical nasal conditions.

Administer with caution to patients who have heart disease; epinephrine may aggravate angina pectoris or produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

The presence of a sulfite in **neffy** should not deter use.

neffy may alter nasal mucosa for up to 2 weeks after administration and increase systemic absorption of nasal products, including **neffy**.

Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions.

Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in patients with the following: hyperthyroidism, Parkinson's disease, diabetes, renal impairment. Epinephrine should be administered with caution in patients with these conditions, including elderly patients and pregnant women.

Most common adverse reactions are nasal discomfort, headache, rhinorrhea, dizziness, nausea, vomiting, throat irritation, nasal congestion, paresthesia, sneezing, upper respiratory tract congestion, epistaxis, rhinalgia, nasal dryness, dry throat, fatigue, and feeling jittery.

These are not all of the possible side effects of **neffy**. To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at [1-877-MY-NEFFY \(877-696-3339\)](tel:1-877-MY-NEFFY) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full [Prescribing Information](#) for **neffy**.

References: 1. **neffy** [prescribing information]. San Diego, CA: ARS Pharmaceuticals, Inc. 2. Data on file. ARS Pharmaceuticals Operations, Inc. 2023.

neffyPRO.com



©2026 ARS Pharmaceuticals Operations, Inc. All rights reserved. "ARS Pharma," the ARS Pharma logo design, "**neffy**," and the **neffy** logo are trademarks or registered trademarks of ARS Pharmaceuticals Operations, Inc. All other trademarks are the property of their respective owners. NEF-US-0003-4 I 06/2026

